Patient registries are fast becoming a critical source of real world data (RWD), especially in rare disease research and development (R&D). A recent article discusses the acceleration in orphan drug approvals and the benefits of the STATinMED RWD Insights tool. “Rare diseases are not so […]
Leveraging RWD to Improve Outcomes for Patients With Mantle Cell Lymphoma
A collaboration between Janssen and Flatiron Health led to advancements in the research and care of patients with Mantle Cell Lymphoma. Using real world data (RWD), investigators assessed how different treatment approaches impacted patient outcomes. “In this interview, researchers from Janssen, […]
Flatiron ResearchX On-Demand Webinar on RWE in Regulatory Submissions
Flatiron ResearchX invited real world evidence (RWE) and pharma leaders to discuss how RWE impacts submissions to regulatory bodies. Available on-demand, the webinar covers RWE applications throughout the research and development pipeline. “This ResearchX session included presentations from Eli […]
Cerner’s First Chief Health Officer Seeks to Leverage EHR RWD to Predict Disease and Improve Patient Outcomes
According to Cerner, Nasim Afsar, MD, MBA, MHM will take on the position of Chief Health Officer in January 2022. Dr. Afsar will guide organizations dedicated to improving patient care, including regulatory, health policy, and patient safety groups. She also intends to use electronic health record […]
RWE Expert and Economist Details Future Global Market Access and Pricing Trends
Economist Ulf Staginnus shared his thoughts on future trends for market access and drug pricing in a recent discussion with The Evidence Base. “In this interview, Ulf Staginnus (Blueprint Medicines, MA, USA) discusses the impact of real-world evidence (RWE) on pricing and market access, alongside […]
New Report Considers Use of Oncology RWE in Successful Submissions to the FDA
In a recent article published in Clinical Cancer Research, investigators analyzed successful submissions of oncology drugs to the Food and Drug Administration (FDA) that utilized real world evidence (RWE). The researchers identified elements criticized by the FDA, including confounding factors, and […]
Certara Leaders Discuss Leveraging RWD to Advance R&D and Meet Global Payers’ Needs
Certara’s Lee Stern and Shawn Bates shared their thoughts on how real world data (RWD) can be leveraged to meet health payers’ needs. Expensive novel treatments, such as those used in oncology or rare disease treatment, require a thorough understanding of the long-term costs they incur. Stern […]
Veradigm Advances R&D and Patient Care Using RWD
Veradigm uses its Electronic Health Record (EHR) software to improve patient care and to advance clinical research using real world data (RWD). Veradigm partners with biopharma companies to address questions related to drug efficacy and safety using its comprehensive patient database that includes […]
Aetion Publishes 2021 eBook Showcasing RWE in Successful FDA Submissions
Aetion has published an eBook following an investigation into when and how real world evidence (RWE) successfully supports submissions to the Food and Drug Administration (FDA). The eBook explores RWE across therapeutic areas and identifies factors that influence external control arms. “Aetion […]
Panalgo VP Discusses Changes to ICER’s Value Assessments Ahead of Mid-November Webinar
HealthEconomics.Com Founder and CEO Dr. Patti Peeples recently spoke with Panalgo’s Matt Sussman regarding changes to the value assessments carried out by the Institute for Clinical and Economic Review (ICER). Real world evidence (RWE) and real world data (RWD) are gaining prominence while the […]
